Q3 FY2026
Filed Nov 9, 2026James River reports Q3 2026 net loss of $189.4 million, or $4.08 per diluted share, driven by a $181.8 million goodwill impairment; adjusted net operating loss of $4.4 million, or $0.10 per diluted share
GAAP net loss available to common shareholders of $(189,409) thousand, including a non-cash $181,831 thousand goodwill impairment. Adjusted net operating loss of $(4,445) thousand versus income of $17,383 thousand a year earlier. Combined ratio of 115.6% versus 94.0%, driven by E&S adverse reserve development of $19.2 million that the company describes as concentrated in a run-off Product Liability portfolio. Gross written premium fell 22% and net earned premium fell 14%. Partial offsets are a 40% decline in Specialty Admitted expenses, a 9% decline in G&A, and a 1% rise in net investment income.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Gross written premiums, Q3 2026GAAP | $186.1M | – | (22) % |
| Net written premiums, Q3 2026GAAP | $105.0M | – | (14) % |
| Net earned premiums, Q3 2026GAAP | $127.7M | – | (14) % |
| Net investment income, Q3 2026GAAP | $22.18M | – | 1 % |
| Private investments net investment income, Q3 2026GAAP | $2.19M | – | 105 % |
| All other investments net investment income, Q3 2026GAAP | $20.00M | – | (4) % |
| Annualized gross investment yield, Q3 2026other | 4.7% | – | – |
| Net realized and unrealized (losses) gains on investments, Q3 2026GAAP | −$2.86M | – | – |
| Other income, Q3 2026GAAP | $670K | – | – |
| Total revenues, Q3 2026GAAP | $147.7M | – | – |
| Losses and loss adjustment expenses, Q3 2026GAAP | $104.4M | – | – |
| Other operating expenses, Q3 2026GAAP | $43.20M | – | – |
| Other expenses, Q3 2026GAAP | $1.16M | – | – |
| Interest expense, Q3 2026GAAP | $5.71M | – | – |
| Amortization of intangible assets, Q3 2026GAAP | $90K | – | – |
| Impairment of goodwill, Q3 2026GAAP | $181.8M | – | – |
| Total expenses, Q3 2026GAAP | $336.4M | – | – |
| Loss before income taxes from continuing operations, Q3 2026GAAP | −$188.7M | – | – |
| Income tax (benefit) expense on continuing operations, Q3 2026GAAP | −$1.40M | – | – |
| Net loss from continuing operations, Q3 2026GAAP | −$187.3M | – | – |
| Net loss from discontinued operations, Q3 2026GAAP | −$133K | – | – |
| Net loss available to common shareholders, Q3 2026GAAP | −$189.4M | – | – |
| Diluted loss per common share, Q3 2026GAAP | $(4.08) | – | – |
| Diluted loss per common share from continuing operations, Q3 2026GAAP | $(4.08) | – | – |
| Adjusted net operating (loss) income, Q3 2026non-GAAP | −$4.45M | – | – |
| Adjusted net operating loss per diluted share, Q3 2026non-GAAP | $(0.10) | – | – |
| Underwriting loss, Q3 2026non-GAAP | −$19.99M | – | – |
| Loss ratio, Q3 2026other | 81.9 % | – | – |
| Expense ratio, Q3 2026other | 33.7 % | – | – |
| Combined ratio, Q3 2026other | 115.6 % | – | – |
| Accident year loss ratio, Q3 2026other | 65.7 % | – | – |
| Pre-tax net adverse reserve development, Q3 2026other | −$20.62M | – | – |
| Cash dividends declared per common share, Q3 2026GAAP | $0.01 | – | – |
| Shareholders' equity at September 30, 2026GAAP | $291.9M | – | – |
| Tangible common equity at September 30, 2026non-GAAP | $367.8M | – | – |
| Tangible common equity per share at September 30, 2026non-GAAP | $7.95 | – | – |
| Tangible equity per share at September 30, 2026non-GAAP | $8.38 | – | – |
| Shareholders' equity per share at September 30, 2026GAAP | $6.31 | – | – |
| Gross written premiums, nine months 2026GAAP | $691.4M | – | – |
| Net written premiums, nine months 2026GAAP | $373.5M | – | – |
| Net earned premiums, nine months 2026GAAP | $402.4M | – | – |
| Net investment income, nine months 2026GAAP | $63.79M | – | – |
| Net realized and unrealized losses on investments, nine months 2026GAAP | −$8.49M | – | – |
| Total revenues, nine months 2026GAAP | $460.4M | – | – |
| Losses and loss adjustment expenses, nine months 2026GAAP | $311.7M | – | – |
| Other operating expenses, nine months 2026GAAP | $138.5M | – | – |
| Impairment of goodwill, nine months 2026GAAP | $181.8M | – | – |
| Total expenses, nine months 2026GAAP | $651.3M | – | – |
| Loss before income taxes from continuing operations, nine months 2026GAAP | −$190.9M | – | – |
| Net loss from continuing operations, nine months 2026GAAP | −$189.5M | – | – |
| Net loss available to common shareholders, nine months 2026GAAP | −$195.9M | – | – |
| Diluted (loss) earnings per common share, nine months 2026GAAP | $(4.23) | – | – |
| Adjusted net operating income, nine months 2026non-GAAP | $11.38M | – | – |
| Adjusted net operating income per diluted share, nine months 2026non-GAAP | $0.24 | – | – |
| Underwriting loss, nine months 2026non-GAAP | −$26.53M | – | – |
| Loss ratio, nine months 2026other | 72.2 % | – | – |
| Expense ratio, nine months 2026other | 34.4 % | – | – |
| Combined ratio, nine months 2026other | 106.6 % | – | – |
| Accident year loss ratio, nine months 2026other | 65.8 % | – | – |
| Cash dividends declared per common share, nine months 2026GAAP | $0.03 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Excess and Surplus LinesGross written premiums $170,404 thousand, (18.8) %. Net written premiums $104,027 thousand, (14.5) %. Losses and LAE excluding retroactive reinsurance $(101,436) thousand, 13.9 % higher. Underwriting loss $(10,793) thousand versus profit of $16,433 thousand. Loss ratio 80.3 % versus 63.5 %; combined ratio 108.5 % versus 88.3 %. Company states the $19.2 million of net adverse development followed its annual Detailed Valuation Review and related primarily to the Product Liability line, a portfolio now fully in runoff. Company states new and renewal submission growth for active divisions increased 8% compared to the prior year quarter. | $126,321 thousand net earned premiums, Q3 2026 | – | (9.9) % |
| Specialty Admitted InsuranceGross written premiums $15,700 thousand, (42.8) %. Net written premiums $983 thousand, (4.2) %. Losses and LAE $(3,104) thousand, (63.3) %. Underwriting expenses $(1,767) thousand versus $(172) thousand, 927.3 % higher. Underwriting loss $(3,481) thousand versus $(352) thousand. Company states Specialty Admitted general and administrative expenses declined 34% in the quarter and 40% year to date. Company states $1.4 million of net adverse development was recorded within this segment. | $1,390 thousand net earned premiums, Q3 2026 | – | (83.2) % |
| Corporate and Other (expenses only, no revenue reported)Other operating expenses of the Corporate and Other segment were $(5,712) thousand versus $(7,227) thousand a year earlier. Company states Corporate general and administrative expenses declined 21% in the quarter. | Other operating expenses $(5,712) thousand, Q3 2026 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Capital returns
- Board declared a cash dividend of $0.01 per share of common stock, payable Thursday, December 31, 2026 to shareholders of record as of Tuesday, December 15, 2026.
- Cash dividends declared per common share were $0.01 in Q3 2026 and $0.01 in Q3 2025; $0.03 for nine months 2026 and $0.03 for nine months 2025.
- Dividends on Series A preferred shares were $(1,969) thousand in Q3 2026 and $(1,969) thousand in Q3 2025; $(5,907) thousand for nine months in both years.
- No share repurchase amounts are printed in the release.
What drove it
- Company states the Q3 net loss was largely driven by the non-cash goodwill impairment of $181.8 million, which it says relates to goodwill added when the Company was acquired by an investor group in 2007 rather than to any acquisition made by the Company.
- Company states the adjusted net operating loss was primarily impacted by adverse reserve development in the E&S segment. E&S net adverse development was $19.2 million on total E&S net reserves of $1.0 billion, driven by a specific portfolio fully in runoff within Product Liability.
- Company states that the reserve additions for E&S were informed by its annual Detailed Valuation Review process completed during the quarter.
- Company states it continues to observe lower frequency and incurred losses in more recent accident years following underwriting changes since 2023.
- Company states net earned premium and net written premium were impacted by $7.2 million of reinsurance reinstatement premiums in nine months 2026 ($9.6 million in nine months 2025), associated predominantly with a single claim within E&S. Zero reinstatement premiums are printed for Q3 2026 versus $3.8 million in Q3 2025.
- Losses and LAE include retroactive reinsurance deferred gain expenses of ($117,000) in Q3 2026 versus $23.5 million in Q3 2025, per the footnote.
- Private investment income was $2,190 thousand, $1.1 million greater than the prior year period. Company attributes this to private credit investments through capital-efficient rated notes, with strong quarterly returns and increased invested balances.
- Net realized and unrealized losses of $2.9 million were driven primarily by unrealized losses within the portfolio's preferred stock holdings, whose fair values were largely impacted by rate increases during the quarter, per the company.
- G&A expenses declined 9% in Q3 and on a year-to-date basis versus prior year periods, per the company.
Concerns
- Q3 2026 GAAP net loss available to common shareholders of $(189,409) thousand, or $(4.08) per diluted share, against $(948) thousand, or $(0.02), in Q3 2025.
- Adjusted net operating loss of $(4,445) thousand versus income of $17,383 thousand a year earlier. Adjusted net operating income was $11,385 thousand for nine months 2026 versus $38,178 thousand.
- Combined ratio of 115.6% in Q3 2026 versus 94.0%, and 106.6% for nine months 2026 versus 97.4%.
- E&S gross written premiums fell 18.8% and net written premiums fell 14.5% in Q3 2026. Company states heightened competition remains across casualty lines.
- Shareholders' equity per share fell to $6.31 from $10.96 a year earlier. Tangible common equity per share was $7.95 versus $8.24 a year earlier.
- Company states adverse reserve development of $19.2 million in E&S, and a further $1.4 million in Specialty Admitted, in Q3 2026.
- Specialty Admitted net earned premiums fell 83.2% and gross written premiums fell 42.8% in Q3 2026.
What to watch
- Whether the company's claim that recent accident years show lower frequency and incurred losses is reflected in the accident year loss ratio, which was 65.7% in Q3 2026 and 65.7% a year earlier.
- Development on the Product Liability portfolio described as fully in runoff, and any further reserve additions outside the annual review.
- Recovery of E&S gross written premium growth, which the company states is supported by 8% growth in new and renewal submissions for active divisions.
- Specialty Admitted premium trajectory, given gross written premiums of $15,700 thousand versus $27,445 thousand a year earlier.
- Tangible common equity recovery, given the company's statement that accumulated other comprehensive loss increased $52.0 million as rates rose during the year.
- Outcome of the November 10, 2026 conference call at 8:30 a.m. Eastern Time, where the company will discuss the results.
Balance sheet and cash flow
- Total assets were $4,292,636 thousand at September 30, 2026 versus $4,859,930 thousand at December 31, 2025.
- Shareholders' equity was $291,877 thousand at September 30, 2026 versus $538,153 thousand at December 31, 2025. Company states the decline was predominantly affected by the non-cash, full impairment of goodwill to $181.8 million in Q3.
- Goodwill and intangible assets were $31,815 thousand at September 30, 2026 versus $213,918 thousand at December 31, 2025.
- Tangible common equity was $367.8 million at September 30, 2026, a 10.5% decrease from $411.0 million at December 31, 2025, as printed by the company. The company states the decline included a $52.0 million increase in accumulated other comprehensive loss, which came as a result of the rise in rates during the year.
- Cash and cash equivalents were $167,903 thousand at September 30, 2026 versus $260,941 thousand at December 31, 2025.
- Reserve for losses and loss adjustment expenses was $2,912,382 thousand at September 30, 2026 versus $3,099,418 thousand at December 31, 2025.
- Reinsurance recoverable on unpaid losses, net was $1,821,124 thousand at September 30, 2026 versus $2,026,110 thousand at December 31, 2025.
- Senior debt was $225,800 thousand and junior subordinated debt was $104,055 thousand at September 30, 2026, both unchanged from December 31, 2025.
- Series A redeemable preferred shares were $133,115 thousand at September 30, 2026, unchanged from December 31, 2025.
- Net investment income of $22.2 million was described as driven by attractive book yields in fixed maturities and strong income from private investments, per the company.
Analysis
James River reported a Q3 2026 GAAP net loss available to common shareholders of $(189,409) thousand, or $(4.08) per diluted share, against $(948) thousand, or $(0.02), a year earlier. The result includes a non-cash goodwill impairment of $181,831 thousand. On an adjusted basis, which the company defines as a non-GAAP measure, the quarter produced a net operating loss of $(4,445) thousand, or $(0.10) per diluted share, compared with income of $17,383 thousand, or $0.32, in Q3 2025. The company states that the impairment does not affect its adjusted net operating results, statutory capital or compliance with debt covenants.
Top-line demand weakened across both segments. Gross written premiums were $186,104 thousand, down 22%, and net earned premiums were $127,711 thousand, down 14%. In E&S, gross written premiums fell 18.8% to $170,404 thousand while the company reports that new and renewal submission growth for active divisions rose 8%. The company describes its posture as disciplined, choosing to focus on smaller accounts and to add only risk that meets its underwriting standards, and it notes that competition remains heightened across casualty lines. Specialty Admitted net earned premiums fell 83.2% to $1,390 thousand.
Underwriting results deteriorated sharply. The consolidated loss ratio was 81.9% against 65.7%, the expense ratio was 33.7% against 28.3%, and the combined ratio was 115.6% against 94.0%. In E&S, the combined ratio was 108.5% against 88.3%. The company attributes the E&S result to $19.2 million of net adverse development from its annual Detailed Valuation Review, concentrated in a Product Liability portfolio now in runoff. The accident year loss ratio of 65.7% was unchanged year over year, so the deterioration sits in prior-year development rather than the current accident year, a point the company itself makes. Expense ratio pressure is also visible even as the company reports G&A down 9%, which the company says reflects reductions in Specialty Admitted and Corporate.
Investment income was steadier. Net investment income rose 1% to $22,185 thousand, with private investment income of $2,190 thousand up 105%, offset by a 4% decline in income from all other investments. The annualized gross investment yield was 4.7% against 4.6%. Net realized and unrealized losses of $(2,857) thousand reflected preferred stock marks, which the company attributes to rate increases in the quarter.
On the balance sheet, shareholders' equity fell to $291,877 thousand from $522,601 thousand at June 30, 2026, and tangible common equity per share fell to $7.95 from $9.01. Senior debt of $225,800 thousand and junior subordinated debt of $104,055 thousand were unchanged from December 31, 2025. Cash and cash equivalents were $167,903 thousand against $260,941 thousand at year end. The Board declared a $0.01 per share dividend payable December 31, 2026. The release does not print operating cash flow, free cash flow, share repurchases or any forward guidance, so the read on capital allocation rests on the dividend and the balance sheet figures alone.
Management, verbatim
E&S submission growth and our market opportunity set remain strong across the franchise as we leverage our investments in technology and further emphasize smaller accounts and greater profitability. During the quarter, we completed our first principles reserve review and while the Company continues to see distinct improvement in overall profitability since 2023, we bolstered reserves in our Product Liability line to address a specific portfolio that is now fully in runoff.
Frank D'Orazio, Chief Executive Officer
Not in the filing
stated, not guessed- No prior-period outlook or forward guidance was provided, so guidance and vs_prior_guidance are empty or null.
- Operating cash flow and free cash flow are not reported in the release.
- Share repurchase activity is not reported in the release.
- Year-over-year percentage changes are not printed for consolidated income statement lines, ratios or non-GAAP lines, so those fields are null.
- Prior-quarter (Q2 2026) income statement figures are not printed, so qoq_change and prior_quarter fields for income statement lines are null.
- Consensus estimates, analyst expectations and share price reaction are not included in the documents.
- The 10.5% decline in tangible common equity is printed against December 31, 2025 and has no same-period prior-year percentage, so the yoy_change for that line is null.
- Segment revenue is printed as net earned premiums; no segment revenue line is labeled revenue in the release.
- The company does not print a segment revenue figure for Corporate and Other.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.